Elucidating the role of excision repair cross-complement group 1 in oral epithelial dysplasia and early invasive squamous cell carcinoma: An immunohistochemical study.
DNA repair proteins
dysplasia
early invasive squamous cell carcinoma
excision repair cross-complement group 1
immunohistochemistry
pathogenesis
Journal
Journal of oral and maxillofacial pathology : JOMFP
ISSN: 0973-029X
Titre abrégé: J Oral Maxillofac Pathol
Pays: India
ID NLM: 101227995
Informations de publication
Date de publication:
Historique:
received:
18
02
2019
revised:
09
07
2019
accepted:
26
07
2019
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
9
6
2020
Statut:
ppublish
Résumé
Oral epithelial dysplasia (OED) is characterized by cellular alterations which have the proclivity of progressing to squamous cell carcinoma. Excision repair cross-complement group 1 (ERCC1) is one of the key proteins involved in nucleotide excision repair (NER) pathway. The expression of ERCC1 has been studied in colorectal, esophageal, ovarian and oral squamous cell carcinoma; but, very few studies have been done to apprehend the expression of ERCC1 in OED and early invasive squamous cell carcinoma (EISCC). The goal of this study is to evaluate the role of ERCC1 in OED and EISCC. Histopathologically diagnosed cases of moderate dysplasia ( The expression of ERCC1 was found to be strong (+3) in EISCC, moderate (+2) in severe dysplasia and mild (+1) in moderate dysplasia. Thus, the results were statistically significant between the three groups ( Disruption in the mechanisms that regulate cell cycle checkpoints and DNA repair mechanism results in genomic instability; these alterations might contribute to carcinoma. ERCC1 is essential to repair the DNA damage induced by various carcinogens. The present study shows significant difference in the expression of ERCC1 between EISCC and OED, which suggests ERCC1 could be used as one of the predictive markers.
Identifiants
pubmed: 32508443
doi: 10.4103/jomfp.JOMFP_60_19
pii: JOMFP-24-20
pmc: PMC7269280
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20-25Informations de copyright
Copyright: © 2020 Journal of Oral and Maxillofacial Pathology.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Clin Cancer Res. 2005 Mar 15;11(6):2215-21
pubmed: 15788669
Clin Cancer Res. 2007 Jun 15;13(12):3753-8
pubmed: 17575242
Braz J Med Biol Res. 2017 Nov 13;51(1):e6822
pubmed: 29160417
Anticancer Res. 2011 Dec;31(12):4135-9
pubmed: 22199271
Br J Cancer. 2008 Jul 8;99(1):167-72
pubmed: 18594541
Head Neck Pathol. 2007 Sep;1(1):61-6
pubmed: 20614284
Biomarkers. 2010 Aug;15(5):379-99
pubmed: 20429839
Carcinogenesis. 1999 Nov;20(11):2125-9
pubmed: 10545415
J Transl Med. 2011 Mar 23;9:31
pubmed: 21426588
BMC Cancer. 2013 Dec 12;13:594
pubmed: 24330540
Ann Transl Med. 2014 Apr;2(4):32
pubmed: 25333008
Cell Cycle. 2013 Oct 15;12(20):3298-306
pubmed: 24036546
J Clin Invest. 1994 Aug;94(2):703-8
pubmed: 8040325
Histopathology. 2011 Feb;58(3):352-60
pubmed: 21323960
Pak J Med Sci. 2013 Sep;29(5):1158-61
pubmed: 24353711
Asian Pac J Cancer Prev. 2016;17(S3):87-91
pubmed: 27165214
Mol Cell Biochem. 2013 May;377(1-2):45-53
pubmed: 23435956
Genes Dev. 1999 Apr 1;13(7):768-85
pubmed: 10197977
Int J Mol Sci. 2017 Jan 16;18(1):
pubmed: 28275213
J Biol Chem. 2010 Feb 5;285(6):3705-12
pubmed: 19940136
BMC Cancer. 2013 Mar 06;13:103
pubmed: 23496813
PLoS One. 2016 Jul 13;11(7):e0159090
pubmed: 27410681